Key result
Novel oral anticoagulants offer advantages over warfarin for treating venous thromboembolism in older adults, including fewer drug interactions and lower bleeding risk, though caution is required.
Why the study?
What is the pathogenesis, diagnosis, and optimal treatment approach for venous thromboembolism in older adults?
What is the pathogenesis, diagnosis, and optimal treatment approach for venous thromboembolism in older adults?
This review highlights that while VTE is common and often underrecognized in older adults, NOACs offer a promising alternative to warfarin with potentially lower bleeding risks, provided modifiable risk factors are managed.
Answers are grounded in this paper and cite their sources.
Supports cautious NOAC preference in older VTE; leaves open dedicated RCTs for confirmation.
Older adults have a significantly greater risk of venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, than younger adults. The cause of this greater risk is thought to be multifactorial, including age-related changes in hemostatic factors and greater comorbid conditions and hospitalizations, but is not completely understood. Moreover, VTE remains underrecognized in older adults and may present atypically. Thus, a low index of clinical suspicion is essential when evaluating older adults with possible VTE. Despite this underrecognition in older adults, the diagnostic approach remains similar for all age groups and includes estimation of pretest probability, measurement of the D-dimer, and imaging. Antithrombotic agents are the mainstay of VTE treatment and, when used appropriately, substantially reduce VTE recurrence and complications. The approval of novel oral anticoagulants (NOACs), including dabigatran, rivaroxaban, apixaban, and edoxaban, provide clinicians with new therapeutic options. In some individuals, NOACs may offer advantages over warfarin, including fewer drug interactions, more-predictable anticoagulation, and lower risk of bleeding. Nevertheless, anticoagulation of VTE in older adults should always be performed cautiously, because age is a risk factor for bleeding complications. Identifying modifiable bleeding risk factors and balancing the risks of VTE recurrence with hemorrhage are important considerations when using anticoagulants in older adults.
No takes yet. Share an insight, caveat, or question.
Johnson et al. (2016) conducted a review in Venous Thromboembolism (VTE). Novel oral anticoagulants (NOACs) vs. Warfarin was evaluated. Novel oral anticoagulants offer advantages over warfarin for treating venous thromboembolism in older adults, including fewer drug interactions and lower bleeding risk, though caution is required.
Synapse has enriched 10 related papers. Consider them for comparative context: